Comparative effectiveness of first, second, and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A systematic review and frequentist network meta-analysis. This is an ASCO ...

Patients with high-risk gastrointestinal stromal tumors (GISTs) had a 60% improvement in 3-year disease-free survival (DFS) with 6 versus 3 years of maintenance imatinib, a randomized trial showed.

Imatinib (Imkeldi) is the first oral liquid TKI approved for multiple cancers, enhancing treatment accessibility and dosing precision. The drug is effective as a first-line treatment, especially in ...

Kura Oncology, Inc. announced the initiation of the KOMET-015 Phase 1 clinical trial, which will evaluate the safety and effectiveness of ziftomenib, an investigational menin inhibitor, in combination ...